Cancer Channel
Related Channels

Generic Zevalin

Zevalin (ibritumomab) is a type of "biologic" medicine, which means it falls under a different set of laws and regulations than most other prescription medications. Under these regulations, manufacturers are not allowed to make any generic versions of biologic drugs. Until these laws change, which is expected to occur at some point, a generic Zevalin is not likely to be available.

Can I Buy Generic Zevalin?

Zevalin® (ibritumomab) is a prescription medication used in the treatment of non-Hodgkin's lymphoma, a cancer of the lymphoid tissue. It is used as part of a treatment regimen that includes rituximab (Rituxan®).
Zevalin is made by Spectrum Pharmaceuticals, Inc. At this time, it is not available in generic form.

When Will a Generic Version Be Available?

Zevalin belongs to a group of medications known as monoclonal antibodies. Like other monoclonal antibodies, Zevalin is considered a "biologic" product. Examples of biologics include blood products, vaccines, enzymes, and certain medicines produced by biotechnology methods. Biologics are under different regulations than most other prescription medications.
Biologic products are medicinal products made using natural resources, such as human and animal cells or microorganisms. These cells or organisms are used to make a complex mixture of proteins or molecules. While other prescription medicines have known and reproducible chemical structures, most biologics are not so easily characterized because of their complexity. This can make it difficult for manufacturers to produce generic versions of biologics.
Previous regulations did not allow generic versions of biologics to be manufactured. Therefore, it was not possible to buy generic biologics. Recently, new laws have cleared the way for the possibility of generic biologics. However, there is still quite a bit of rulemaking to be done.
At this time, it is not entirely known when a generic version of Zevalin will be available. Even after the laws and regulations are changed to allow the manufacturing of generic biologics, it is likely that Zevalin will still be protected from generic competition by patents for several years.
The medicine was approved by the U.S. Food and Drug Administration (FDA) in February 2002. It is not clear when the patents will expire, as the FDA does not yet list applicable patents for biologics like it does for other medications.
5 Easy Tips to Manage Visitors During Cancer Treatment

Zevalin Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.